Navigation Links
Syndax's Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer
Date:9/11/2013

WALTHAM, Mass., Sept. 11, 2013 /PRNewswire/ -- Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy. Entinostat is an investigational histone deacetylase inhibitor (HDACi) set to begin Phase 3 testing in combination with exemestane in postmenopausal women with metastatic ER+ breast cancer who have progressed on hormonal therapy.

The Breakthrough Therapy designation for entinostat is based on data from the completed Phase 2 ENCORE 301 study, in which entinostat was shown to extend both progression-free survival and overall survival when added to exemestane in postmenopausal women with ER+ metastatic breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor and with a very acceptable tolerability profile. A Phase 3 trial, planned to begin enrolling patients in the first quarter of 2014 is currently being developed by the ECOG-ACRIN Cancer Research Group, which would conduct the study under the sponsorship of the Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI).

"The FDA's decision to designate entinostat a Breakthrough Therapy is important validation of the drug's therapeutic potential in women with advanced breast cancer," said Arlene M. Morris, Syndax's chief executive officer. "Currently, women with ER+ breast cancer who have progressed on hormonal therapy have limited therapeutic options. Entinostat's epigenetic mechanism may reverse resistance to hormonal therapy, delaying the need for toxic chemotherapeutic agents and improving survival when given in combination with a
'/>"/>

SOURCE Syndax Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries
2. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
3. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
4. NextDocs Receives $13.5 Million in Funding to Fuel Expansion
5. TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States
6. Unique New PIR Knee System Receives CE Mark
7. EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease
8. Mylan Acquisition of Agila Receives Approval from Indias Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
9. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
10. HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Destination Therapy Trial
11. Magellan Diagnostics Receives FDA Clearance for LeadCare Ultra Bench-top Clinical Lead Analyzer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ... ("Biotie") to end the option held by Biotie to ... further development of NRL-1 (intranasal diazepam) for pediatric and ... Over the past year, Biotie has advanced the ... preparation for the pivotal clinical work required for NDA ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... privately-held therapeutic device company, today announced that DEKRA and Health ... Matrix for clinical use and sale in Europe and Canada. ... resistant, and absorbable putty designed to rapidly stop bleeding when ... cut bone is a problem in many operative procedures including ...
... announces that a new market research report is available ... Deals Analysis 2011 http://www.reportlinker.com/p0180789/Medical-Equipment-Annual-Deals-Analysis-2011.html ... Summary GlobalData,s "Medical Equipment ... of data and trend analysis on mergers and acquisitions ...
Cached Medicine Technology:ORTHOCON® Receives CE Mark and Health Canada Medical Device License for HEMASORB® 2Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 2Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 3Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 4Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 5Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 6Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 7Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 8Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 9Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 10Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 11Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 12Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 13Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 14Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 15Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 16
(Date:7/14/2014)... 2014 According to the Boost Your Bust book ... women who want to learn how to increase the size of ... of 7 chapters including:, , Chapter 1 – ... Chapter 2 – How Natural Breast Enlargement Works , ... Bigger , Chapter 4 – The Groundwork , ...
(Date:7/14/2014)... Vaginal Mesh lawsuit claims continue to mount ... manufacturers in the U.S. District Court, Southern District of ... complaints are pending against pelvic mesh manufacturers that include ... No. 2325), and C.R. Bard, Inc., (MDL No. 2187). ... lawsuit claims pending, according to statistics from the U.S. ...
(Date:7/14/2014)... that promote mental activity, and moderate physical activity ... development of Alzheimer,s disease and dementia in later ... the Alzheimer,s Association International Conference 2014 (AAIC 2014) ... 2014 also showed that sleep problems especially ... may increase dementia risk in veterans. Additionally, in ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 Love Digits ... iTunes, called Love Digits. The App brings ancient astrology ... alike to quantify their compatibility using a five-star rating ... two people can instantaneously test their compatibility for love ... measures. , The app’s five-star rating system generates a ...
(Date:7/14/2014)... Summer is the best season of the ... beach, swimming and other outdoor adventures. The promotional product experts ... and healthy all summer long. The promo product gurus at ... must-have custom imprinted products everyone must have on hand this ... sunblock. Sunscreen helps protect skin from harmful UV ...
Breaking Medicine News(10 mins):Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 3Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 4Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 6Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 2Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 3Health News:Why These Three Summer Essentials from 4AllPromos Can Improve Summer 2
... BROOK, Ill. Radiologists who interpret a high volume of ... determining which suspicious lesions are not malignant, according to a ... of Radiology . "Contrary to our expectations, we ... study,s lead author, Diana S.M. Buist, Ph.D., M.P.H., senior investigator ...
... errors isn,t quite as new as it seems. A Johns ... the turn of the last century, has turned up copious ... suggestions for preventing those mistakes in the future. Authors ... Surgery , suggest that such open documentation may have played ...
... MONDAY, Feb. 21 (HealthDay News) -- Implementing practical, environmentally ... could reduce health-care costs without compromising patient safety, says ... facilities are a major source of waste products, producing ... 4 billion pounds a year. Nearly 70 percent of ...
... By Serena Gordon HealthDay Reporter , MONDAY, Feb. ... in northern climates aren,t imaging that their misery is lasting ... for people living in some northern U.S. states, the length ... weeks, and for people living in some areas of Canada, ...
... , MONDAY, Feb. 21 (HealthDay News) -- Seniors who ... researchers say. The study from Rush University in Chicago ... no type of disability at the start of the study ... provided information about their social activities, such as going out ...
... million grant from the National Institutes of Health (NIH) ... biomarkers that may be linked to the development and ... in children. Nationwide Children,s is home to the only ... with an NIH-sponsored clinical study. A hemangioma is ...
Cached Medicine News:Health News:Higher volume reduces false positives in screening mammography 2Health News:Famed neurosurgeon's century-old notes reveal 'modern' style admission of medical error 2Health News:Going 'Green' May Cut Hospital Costs 2Health News:Climate Change Extending Ragweed Season in Colder Climes: Study 2Health News:Climate Change Extending Ragweed Season in Colder Climes: Study 3Health News:Busy Social Life May Stave Off Disability in Elderly 2Health News:$1.9 million NIH grant supports research in the most common soft tissue tumor in children 2
... complete line of enteric disease ... and monoclonal/polyclonal antibody-based ELISA tests ... pathogens in fecal specimens. Our ... difficile, Entamoeba histolytica, Giardia, Cryptosporidium ...
... II test is also available with Inverness ... greatly reduces the hands-on time required to ... testing. The Fecal-Quik-Prep device is a unique ... amount of hands-on time required to prepare ...
... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Medicine Products: